Abstract
Regular cancer screening is critical for early cancer detection. Cancer screening tends to be burdensome, invasive, and expensive, especially for a comprehensive multi-organ check. Improving the rate and effectiveness of routine cancer screenings remain a challenge in health care. Multi-cancer early detection (MCED) is an exciting concept and a potentially effective solution for addressing current issues with routine cancer screening. In recent years, several technologies have matured for MCED, such as identifying cell-free tumor DNA in blood or using organisms such as Caenorhabditis elegans as a tool for early cancer detection. In Japan, N-NOSE is a commercially available multi-cancer detection test based on the chemotaxis of C. elegans using a urine sample showing 87.5% sensitivity and 90.2% specificity. In this review, we focus on using C. elegans as a powerful biosensor for universal cancer screening. We review N-NOSE clinical research results, spotlighting it as an effective primary cancer screening test.
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference71 articles.
1. Cancer Information Service Japan, Cancer Statistics in Japan
https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2021.pdf
2. Cancer screening recommendations: an international comparison of high income countries
3. Cancer Screening in the European Union (2017). Report on the Implementation of the Council Recommendation on Cancer Screening;Ponti,2017
4. IARC Handbooks of Cancer Prevention. Volume 10: Cervix Cancer Screening,2005
5. Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献